Hiroshima University

Start of Clinical Research with Hiroshima University on Photon-Counting CT

Retrieved on: 
Tuesday, April 9, 2024
Biomedicine, X-ray, Congress, Medicine, Ōtawara, Medical imaging, Research, Canon Medical Systems Corporation, Society, Deep learning, Outline of health sciences, Hiroshima University

Tustin, California, April 09, 2024 (GLOBE NEWSWIRE) -- Canon Medical Systems Corporation (hereinafter "Canon Medical"; President and CEO: Toshio Takiguchi; headquarters: Otawara, Tochigi, Japan) and Hiroshima University (President: Mitsuo Ochi; location: Higashi-Hiroshima, Hiroshima, Japan) began clinical research.

Key Points: 
  • Tustin, California, April 09, 2024 (GLOBE NEWSWIRE) -- Canon Medical Systems Corporation (hereinafter "Canon Medical"; President and CEO: Toshio Takiguchi; headquarters: Otawara, Tochigi, Japan) and Hiroshima University (President: Mitsuo Ochi; location: Higashi-Hiroshima, Hiroshima, Japan) began clinical research.
  • PCCT is expected to become the next generation of X-ray CT.
    Canon Medical entered into a basic agreement on joint clinical research with Hiroshima University on November 1, 2023, *1 and clinical research began, led by Professor Kazuo Awai of the Department of Diagnostic Radiology at Hiroshima University Graduate School of Biomedical and Health Sciences.
  • Through this latest clinical research, we are aiming to take another step forward towards the practical application of PCCT.
  • We will accelerate development of PCCT by feeding back the results of this clinical research into improvement of the system.

Rochester Institute of Technology takes its place on international stage at G7 to advance semiconductor development

Retrieved on: 
Monday, May 22, 2023
Workforce, RIT, Faculty, Partnership, Kate Gleason College of Engineering, University, Virginia Tech, CET, College, U.S. Department of Defense Strategy for Operating in Cyberspace, Education, Electronics, Assembly, NSF, Wise, Teaching, National Science Foundation, University of Washington, Rochester Institute of Technology, Kyushu University, KGCOE, Research, Tohoku University, Element, Nagoya University, Government, Computer, Electronic, Hiroshima University, Future, Student, Sri Krishna College of Engineering & Technology, Rensselaer Polytechnic Institute, Laboratory, MOU, Purdue University, Tokyo Institute of Technology, Woman, Boise State University, Memory, Gender, Electricity, Commerce, Nursing, Management, Semiconductor, Engineering, Micrometre, STEM

ROCHESTER, N.Y., May 22, 2023 /PRNewswire-PRWeb/ -- Rochester Institute of Technology is one of six U.S. universities named as part of an international partnership to improve competitiveness in computer chip design, development, and manufacturing.

Key Points: 
  • Micron Corp. and the National Science Foundation announced the partnership and signed a Memorandum of Understanding (MOU) at the 2023 G7 Summit in Japan.
  • ROCHESTER, N.Y., May 22, 2023 /PRNewswire-PRWeb/ -- Rochester Institute of Technology is one of six U.S. universities named as part of an international partnership to improve competitiveness in computer chip design, development, and manufacturing.
  • Through the UPWARDS partnership, RIT will participate in curriculum development, student and faculty exchanges, research projects, and Micron's Women in Semiconductors (WiSe) program.
  • It is expected to create thousands of new jobs in an effort to increase production of computer chip technology.

MIRAILAB BIOSCIENCE Inc., the Leading Company in NMN Supplements Announces Health Mailing Kit Series

Retrieved on: 
Thursday, February 2, 2023
Research, Technology, Biotechnology, General Health, University, Health, Data Management, Science, Education, Artificial Intelligence, Postgraduate education, Diet, Stomach cancer, Smoking, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Mitochondrion, Sugar, Ageing, Biomedicine, Breast cancer, Health status of Asian Americans, Cancer, Organelle, Dyslipidemia, Obesity, Effect, Drinking, Oxygen, Cell, NMN, University of Tokyo, Database, Nutrient, Diabetes, Mouth, Liver cancer, Prostate cancer, NAD, Risk, HQ, Hypertension, Outline of health sciences, Stroke, Lung cancer, Disease, Hiroshima University, Dementia, Quantification (science), Fats, Defense, Washington University in St. Louis, Mail order, Dietary supplement, Palladium, Copper, Nicotinamide mononucleotide

MIRAILAB BIOSCIENCE Inc. (HQ: Tokyo, Japan; CEO: Megumi Tanaka) is proud to announce our new product category: the health mailing kit series.

Key Points: 
  • MIRAILAB BIOSCIENCE Inc. (HQ: Tokyo, Japan; CEO: Megumi Tanaka) is proud to announce our new product category: the health mailing kit series.
  • Just swab your mouth, send us the sample and receive an analysis report informing you of your present and future health.
  • We were the first company in the world to market NMN supplements, and the pioneers of human clinical studies (“Assessment of Effects of Long-term Administration of Nicotinamide Mononucleotide (NMN)”, with Hiroshima University, the Graduate School of Biomedical & Health Sciences.)
  • Soon, we plan to add new products to our lineup of mailing kits and expand to new markets.

First Japanese Institution to Utilize SOPHiA GENETICS' Myeloid Plus Solution

Retrieved on: 
Tuesday, February 22, 2022
Hiroshima University, U.S. Securities and Exchange Commission, Software as a service, Partnership, Solution, Prognosis, Twitter, Diagnosis, Sophia, Radiation, Research, Medicine, Hitachi, Adoption, Sophia Genetics, LinkedIn, Multimedia, NGS, Instagram, Forward-looking statement, GENETICS, Patient, Technology, Society, CEO, Department, Hospital, Pharmaceutical industry, Medical device, Medical imaging, Hematology

Hiroshima University aimed to establish a framework where the NGS-based testing would become a routine part of clinical diagnosis for myeloid neoplasms.

Key Points: 
  • Hiroshima University aimed to establish a framework where the NGS-based testing would become a routine part of clinical diagnosis for myeloid neoplasms.
  • Leveraging the SOPHiA DDM Platform's unique algorithmic capabilities, the researchers from Hiroshima University detailedtheir experience with the first 24 samples of myeloid solution collected and analyzed as part of a research project to evaluate the clinical utility of NGS testing for myeloid malignancies.
  • "SOPHiA GENETICS' Myeloid Plus Solution is one of the best examples I have ever seen in terms of its ease of use and wide coverage."
  • In partnership with Hitachi, discussions continue with additional Japanese institutions who may also benefit from SOPHiA GENETICS for oncohematological cancer research.

First Japanese Institution to Utilize SOPHiA GENETICS' Myeloid Plus Solution

Retrieved on: 
Tuesday, February 22, 2022
Hiroshima University, U.S. Securities and Exchange Commission, Software as a service, Partnership, Solution, Prognosis, Twitter, Diagnosis, Sophia, Radiation, Research, Medicine, Hitachi, Adoption, Sophia Genetics, LinkedIn, NGS, Instagram, Forward-looking statement, GENETICS, Patient, Technology, Society, CEO, Department, Hospital, Pharmaceutical industry, Medical device, Medical imaging, Hematology

Hiroshima University aimed to establish a framework where the NGS-based testing would become a routine part of clinical diagnosis for myeloid neoplasms.

Key Points: 
  • Hiroshima University aimed to establish a framework where the NGS-based testing would become a routine part of clinical diagnosis for myeloid neoplasms.
  • Leveraging the SOPHiA DDM Platform's unique algorithmic capabilities, the researchers from Hiroshima University detailedtheir experience with the first 24 samples of myeloid solution collected and analyzed as part of a research project to evaluate the clinical utility of NGS testing for myeloid malignancies.
  • "SOPHiA GENETICS' Myeloid Plus Solution is one of the best examples I have ever seen in terms of its ease of use and wide coverage."
  • In partnership with Hitachi, discussions continue with additional Japanese institutions who may also benefit from SOPHiA GENETICS for oncohematological cancer research.

School of Life Sciences and Technology, Indonesia Wins XVI Fujio Cup Quiz in NCRM NICHE 2021; Rajalakshmi Engineering College, India, Emerge Runners.

Retrieved on: 
Tuesday, October 19, 2021
University, Stem Cells, Biotechnology, Education, Other Health, Diabetes, Health, General Health, Research, Infectious Diseases, Science, Kyoto University, Virus, Endoplasmic reticulum stress in beta cells, School, List of life sciences, Centre for Regenerative Medicine, Technology, NASH, Regenerative medicine, Rajalakshmi Engineering College, Medical school, FCQ, B cell, Diabetes, Trust, Multimedia, Yokohama City University, GN, Research, NIMHANS, TN, Autism spectrum, University, Ensō, Global health, NHS trust, CSO, Longevity, National Centre for Science Information, Partnership, University of Toronto, NAFLD, GSZ, Cell Transplantation, Non-alcoholic fatty liver disease, NCRM, Solution, University of Cologne, Lists of diseases, EELS, COVID-19, XVI, Hiroshima University, Kasturba Medical College, Pharmaceutical industry

This press release features multimedia.

Key Points: 

Acuity Brands Filtered Far-UVC Module with Ushio Care222 Technology is the First to be UL Certified

Retrieved on: 
Monday, August 9, 2021
Technology, Health care, School, GLOBE, Bacteria, UL, Atmosphere, Acuity Brands, Skin, Regulation of tobacco by the U.S. Food and Drug Administration, Hiroshima University, GUV, UVC, Severe acute respiratory syndrome coronavirus 2, UV, NYSE, Electronics, Awareness, IEC 62471, Human, IEC, Lighting, Columbia University, Food, Research, Hospital, Virus, Disinfectant, Pharmaceutical industry, Medical device, Fused quartz

The UL Recognized Component certification paves the way for incorporating the module into a variety of Acuity Brands LED lighting products to deliver a measured 222nm far-UVC dosage in occupied spaces.

Key Points: 
  • The UL Recognized Component certification paves the way for incorporating the module into a variety of Acuity Brands LED lighting products to deliver a measured 222nm far-UVC dosage in occupied spaces.
  • The certification process followed by UL included an assessment to IEC 62471 for the GUV module when installed and used according to instructions, said Schimmelpfenning.
  • An important part of the Care222 far-UVC module development involved the creation of patent-pending dosing electronics by Acuity Brands.
  • The completed module is an outgrowth of the 2020 strategic alliance agreement between Acuity Brands and Ushio America which granted Acuity Brands exclusive rights in North America to incorporate Ushios Care222 far-UVC disinfection* technology into Acuity Brands luminaires.